What Odyssey Therapeutics does

Odyssey Therapeutics is a Boston-based, publicly traded clinical-stage biopharmaceutical company (Nasdaq: ODTX, IPO May 2026) founded in 2021 by Gary D. Glick, focused on developing precision immunomodulators and protein therapeutics for patients with autoimmune and inflammatory diseases. The company's scientific thesis targets upstream signaling nodes in the innate immune system — notably scaffolding inhibition of RIPK2 (OD-001) and IRAK4, SLC15A4/TASL blockade (OD-002) and selective TNFR2 agonism (OD-003) — to address cytokine redundancy that limits current downstream cytokine blockers. The pipeline comprises eight declared programs spanning ulcerative colitis, Crohn's disease, lupus, atopic dermatitis, asthma, COPD and additional B cell-mediated and dermatologic indications.

Name

Odyssey Therapeutics

Legal name

Odyssey Therapeutics, Inc.

Website

https://odysseytx.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Immunology Therapeutics

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Immunomodulatory therapeutics
• Autoimmune disease drugs
• Clinical-stage biopharmaceutical
• Precision oncology medicines
• Innate immune therapeutics

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Pre-revenue clinical-stage biotech: Odyssey is a clinical-stage biopharmaceutical company with no approved products and no product revenue; reported a 33.5% year-over-year revenue decline and net loss of $148.6 million in 2025, with operating losses of $157.1 million. Future revenue expected from commercialization of internally-discovered small molecule and protein therapeutics for autoimmune and inflammatory diseases.
2. Future pharmaceutical product sales: Management aims to build a 'little large pharma' and potentially pursue commercialization independently rather than relying on early acquisition deals, indicating intent to capture downstream product revenue across autoimmune and inflammatory indications.
3. Potential collaboration and licensing revenue: Strategic collaborations with partners such as Takeda (Entyvio combination), Johnson & Johnson, Terray, and Spark Biopharma suggest future potential for collaboration, licensing, milestone, or royalty-based revenue streams.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing precision immunomodulators and oncology medicines that target upstream signaling nodes in the innate immune system to treat autoimmune and inflammatory diseases. Its pipeline consists of small molecule and protein therapeutic candidates — including the lead RIPK2 scaffolding inhibitor OD-001 (Phase 2a in ulcerative colitis), the SLC15A4 inhibitor OD-002, the TNFR2 agonist OD-003, a TSLP/IL-33 bispecific antagonist, an IRAK4 scaffolding inhibitor and an IRF5 inhibitor — supported by a proprietary AI/ML drug discovery platform enhanced by quantum machine learning from the acquired company Rahko.

Product overview

Odyssey Therapeutics operates a single clinical-stage biopharmaceutical platform focused on discovering, developing, and commercializing precision medicines for autoimmune and inflammatory diseases. Its portfolio is unified around a strategy of targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation. The core offerings include clinical-stage small molecule candidates OD-001 (RIPK2 scaffolding inhibitor) and OD-002 (SLC15A4 inhibitor), protein therapeutic OD-003 (TNFR2 agonist), and earlier-stage programs including a TSLP/IL-33 bispecific antagonist, an IRAK4 scaffolding inhibitor, and an IRF5 inhibitor (in collaboration with Terray). These candidates are supported by Odyssey's proprietary AI/ML drug discovery platform, which integrates medicinal and computational chemistry, structural biology, genetics, and pharmacology to accelerate the identification and development of novel therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• OD-001: Oral small molecule RIPK2 scaffolding inhibitor; lead product candidate in Phase 2 for ulcerative colitis and Crohn's disease.
• OD-002
• OD-003

Products and services

• OD-001 (RIPK2 Scaffolding Inhibitor) Oral small molecule RIPK2 scaffolding inhibitor designed to block downstream pathway signaling and activation of pro-inflammatory cells of both innate and adaptive immune systems by blocking multiple validated cytokines (TNF, TL1A, IL-23); in development for ulcerative colitis and Crohn's disease.
• OD-002 (SLC15A4 Inhibitor) Oral small molecule designed to selectively block TLR7/8/9-mediated activation of IRF5 via SLC15A4, intended as a first-in-class approach to block disease-relevant signaling while retaining other host defense functions of IRF5; targets lupus and B cell-mediated diseases.
• OD-003 (TNFR2 Agonist) Protein therapeutic designed to selectively agonize TNFR2 on Treg cells to increase Treg number, improve immunosuppressive function and tissue homing, and enable stable immunosuppressive phenotype; addresses shortcomings of IL-2 approaches.
• TSLP/IL-33 Bispecific Antagonist Bispecific antagonist designed to address upstream cytokine redundancy and improve suppression of inflammation in asthma and COPD by targeting two alarmins (TSLP and IL-33) with redundant function.
• IRAK4 Scaffolding Inhibitor Oral small molecule scaffolding inhibitor designed to block inflammatory signaling by the myddosome, addressing shortcomings of kinase inhibitors and degraders by achieving desired pharmacology to block cytokine production across disease-relevant cell types.
• IRF5 Inhibitor (Terray collaboration) Small molecule inhibitor of IRF5 being co-developed with Terray Therapeutics as a complementary strategy to Odyssey's wholly owned SLC15A4 inhibitor for targeting the interferon pathway across different diseases.

Quantifiable outcome

• 27% clinical remission and 61% clinical response in Phase 2a monotherapy trial of OD-001 in moderate to severe ulcerative colitis
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Five partnerships are on record, tiered core.

• Takeda Pharmaceutical Company LimitedcoreStrategic or Co-development PartnerCombination clinical collaboration: Odyssey's lead RIPK2 inhibitor OD-001 is being tested in combination with Takeda's marketed Entyvio (vedolizumab) in a Phase 2a trial for ulcerative colitis (per the Odyssey CEO commentary). $135 million of IPO proceeds earmarked for the OD-001 monotherapy and Entyvio combination Phase 2 trials.
• Johnson & JohnsoncoreStrategic or Co-development PartnerReported as a collaboration partner on Odyssey's pipeline of autoimmune disease treatments (mentioned alongside Terray Therapeutics in coverage of the September 2025 Series D round).
• Terray TherapeuticscoreStrategic or Co-development PartnerCollaboration to develop a small molecule inhibitor of IRF5; IRF5 inhibition is positioned as a complementary strategy to Odyssey's wholly owned SLC15A4 inhibitor for targeting the interferon pathway across different diseases.
• Spark BiopharmacoreStrategic or Co-development PartnerCollaboration to develop autoimmune and inflammatory disease drugs using Spark's pDOS technology within Odyssey's research strategy; intended to diversify Odyssey's development pipeline.
• RahkocoreTechnology or IntegrationAcquisition (January 2022) of London-based machine learning company Rahko to accelerate drug discovery through quantum machine learning technology; several Odyssey programs in lead optimization stages reportedly leveraged Rahko's capabilities.

Scale indicators20 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Apogee Therapeutics: Clinical-stage immunology company developing biologics for atopic dermatitis, asthma, COPD, and other inflammatory diseases. Closely comparable in stage, indication focus, and modality mix to Odyssey's pipeline.
• Prometheus Biosciences: Clinical-stage IBD and immunology company acquired by Merck for ~$10.8B in 2023. Directly comparable to Odyssey's RIPK2/IBD strategy and serves as a key recent precedent for valuation of late-clinical-stage autoimmune biotechs.
• Morphic Holding: Clinical-stage oral small molecule company developing integrin inhibitors for autoimmune diseases (IBD, fibrosis). Acquired by Eli Lilly for ~$3.2B in 2024; a direct comp for Odyssey's oral small molecule immunology strategy.
• Dice Therapeutics: Clinical-stage company developing oral IL-17 small molecule inhibitors for psoriasis and other autoimmune diseases; acquired by Eli Lilly for ~$2.4B in 2023. Comparable to Odyssey in modality (oral small molecules) and immunology focus.
• MoonLake Immunotherapeutics: Clinical-stage immunology company developing nanobody-based therapies (sonelokimab) for inflammatory skin and joint diseases. Comparable in clinical stage, indication focus, and capital intensity to Odyssey.
• Acelyrin: Clinical-stage immunology company developing monoclonal antibodies for inflammatory diseases (e.g., izokibep for psoriatic arthritis/hidradenitis suppurativa). Directly comparable in stage, immunology focus, and biotech scale.
• Pliant Therapeutics: Clinical-stage small molecule company developing integrin-based therapies for fibrotic and inflammatory diseases. Comparable in clinical stage, small molecule modality, and chronic inflammatory disease focus.

Broad incumbents

• AbbVie: Global pharmaceutical leader with dominant autoimmune franchises (Humira, Skyrizi, Rinvoq) across IBD, dermatology, and rheumatology. Sets the competitive baseline Odyssey must beat in target indications.
• Bristol Myers Squibb: Large pharmaceutical company with significant immunology franchise (Zeposia, Sotyktu) in IBD, psoriasis, and lupus. Competes in the same autoimmune indications Odyssey is targeting.
• Takeda Pharmaceutical: Global pharmaceutical company and Odyssey's combination trial partner for OD-001 + Entyvio. Competes directly in IBD and immunology and represents a potential strategic commercialization partner or acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/odyssey_tx
• LinkedInlinkedin.com/company/odyssey-tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors30 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Odyssey Therapeutics